Q1 2026 · 13F-HR/A
Remedium Capital Partners, LLCholdings as filed
Filed 2026-05-19 · accession 0002104501-26-000010
$281.2M
Reported value
6
Positions
2026-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 687604108 | ORKA | Oruka Therapeutics Inc | $76.8M | 27.3% | 1,565,661 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics Inc | $73.5M | 26.1% | 1,456,231 | Common | SOLE |
| 36322Q206 | DMRA | Damora Therapeutics Inc | $53.0M | 18.8% | 2,045,473 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $49.1M | 17.5% | 583,591 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $22.2M | 7.88% | 1,577,750 | Common | SOLE |
| 38000Q201 | — | Crescent Biopharma Inc | $6.6M | 2.36% | 361,250 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.